IBSOLVMIR® can improve the efficacy in cell therapy

Cell therapies are associated with graft loss. It involves activation of the complement and coagulation cascades when cells come into contact with blood, ultimately resulting in cell death. IBSOLVMIR is an infusion product that inhibits IBMIR and alleviates its detrimental effects when administered during transplantation. In addition, IBSOLVMIR help cells pass through the lung and reach their intended site and once there, it promotes the formation of new vessels and engraftment.



Developed to improve islet cell transplantation for treatment of patients with severe diabetes and chronic pancreatitis

Suitable for use with several cell types

Applicable to a range of regenerative cell therapies

Improves viability of engrafted cells resulting in higher efficacy and improved patient outcomes

Reported benefits

Independent studies have demonstrated:

Pipeline for IBSOLVMIR

Phase I
Phase II
Phase III
Phase IV

Development phases

IBSOLVMIR is well documented in several safety and toxicology studies. Efficacy has been reported in a low-dose Phase 2 study.

For more information, please refer to www.clinicaltrials.gov

Completed clinical studies

Patients with severe diabetes were treated with IBSOLVMIR at the time of islet transplantation surgery. They showed improvement to the same extent as compared to the maximum dose treatment with heparin.

IBSOLVMIR has been administered to 69 healthy volunteers and 10 patients with severe diabetes, without drug-related safety concerns.

Ongoing clinical studies

TikoMed is currently performing a phase 2 clinical study in islet transplantation for brittle diabetes patients. The study will include 18 patients, 12 receiving islet transplantation in combination with TikoMed’s drug IBSOLVMIR and 6 patients in a control group receiving standard of care.

Centers included are Huddinge Hospital, Uppsala University and Oslo University Hospital. PI is Torbjörn Lundgren, MD, PhD.